Investment firms Shanghai Fosun Pharmaceutical Co. Ltd has formed a partnership with seven other investors to form an investment fund that plans to invest ¥5 billion (US$695M) in local biotech and med-tech companies in Shenzhen, China UK healthcare investor RYSE Asset Management has closed a new fund to support start-ups involved in digital health and […]
Research led by Curve CSO Professor Ali Tavassoli’s laboratory at University of Southampton Landmark paper on dual HIF-1 and HIF-2 inhibitor that works by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β Southampton, UK, 26 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular […]
Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024 26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, […]
Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024. Read more…
Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio 20 March 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received a Notice of Allowance from the US Patent Office in […]
